X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DISHMAN PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DISHMAN PHARMA ABBOTT INDIA/
DISHMAN PHARMA
 
P/E (TTM) x 43.2 25.1 172.3% View Chart
P/BV x 10.8 3.3 322.5% View Chart
Dividend Yield % 0.6 0.7 93.6%  

Financials

 ABBOTT INDIA   DISHMAN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
DISHMAN PHARMA
Mar-16
ABBOTT INDIA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,015374 1,606.6%   
Low Rs3,707129 2,875.9%   
Sales per share (Unadj.) Rs1,236.9197.8 625.3%  
Earnings per share (Unadj.) Rs122.221.2 576.2%  
Cash flow per share (Unadj.) Rs129.034.7 371.5%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %0.70.8 90.6%  
Book value per share (Unadj.) Rs521.2179.9 289.8%  
Shares outstanding (eoy) m21.2580.69 26.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.91.3 308.9%   
Avg P/E ratio x39.811.9 335.3%  
P/CF ratio (eoy) x37.77.2 520.0%  
Price / Book Value ratio x9.31.4 666.7%  
Dividend payout %28.69.4 303.7%   
Avg Mkt Cap Rs m103,29620,306 508.7%   
No. of employees `0003.00.8 356.6%   
Total wages/salary Rs m3,3705,355 62.9%   
Avg. sales/employee Rs Th8,891.819,252.7 46.2%   
Avg. wages/employee Rs Th1,140.06,459.5 17.6%   
Avg. net profit/employee Rs Th878.32,064.1 42.6%   
INCOME DATA
Net Sales Rs m26,28415,961 164.7%  
Other income Rs m504265 190.1%   
Total revenues Rs m26,78916,226 165.1%   
Gross profit Rs m3,6654,103 89.3%  
Depreciation Rs m1441,091 13.2%   
Interest Rs m8944 0.9%   
Profit before tax Rs m4,0172,334 172.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,421624 227.9%   
Profit after tax Rs m2,5961,711 151.7%  
Gross profit margin %13.925.7 54.2%  
Effective tax rate %35.426.7 132.4%   
Net profit margin %9.910.7 92.1%  
BALANCE SHEET DATA
Current assets Rs m14,44611,018 131.1%   
Current liabilities Rs m4,7259,517 49.6%   
Net working cap to sales %37.09.4 393.3%  
Current ratio x3.11.2 264.1%  
Inventory Days Days51110 46.5%  
Debtors Days Days2035 56.1%  
Net fixed assets Rs m1,11316,304 6.8%   
Share capital Rs m213161 131.7%   
"Free" reserves Rs m10,80812,907 83.7%   
Net worth Rs m11,07614,516 76.3%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m16,24129,805 54.5%  
Interest coverage x497.03.5 14,317.6%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.60.5 302.2%   
Return on assets %16.08.9 180.0%  
Return on equity %23.411.8 198.8%  
Return on capital %36.317.5 207.3%  
Exports to sales %0.624.8 2.5%   
Imports to sales %12.63.7 338.3%   
Exports (fob) Rs m1623,956 4.1%   
Imports (cif) Rs m3,322596 557.2%   
Fx inflow Rs m2684,952 5.4%   
Fx outflow Rs m3,927697 563.6%   
Net fx Rs m-3,6594,255 -86.0%   
CASH FLOW
From Operations Rs m2,5142,786 90.2%  
From Investments Rs m-800-1,529 52.3%  
From Financial Activity Rs m-803-941 85.3%  
Net Cashflow Rs m912316 288.2%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 3.7 213.5%  
FIIs % 0.1 12.7 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 22.1 77.4%  
Shareholders   18,270 46,261 39.5%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 20, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS